Yeast Engineered to Produce Beta-Carotene and Longevity-Linked Carotenoids at Scale
Synthetic biology transforms yeast into factories for beta-carotene, astaxanthin, and retinol — potent antioxidants with anti-aging potential.
Summary
Researchers at Imperial College London reviewed the latest advances in engineering yeast — particularly Saccharomyces cerevisiae and Yarrowia lipolytica — to produce beta-carotene and its derivatives. These compounds include xanthophylls like astaxanthin and zeaxanthin, and apocarotenoids like retinol and crocetin, all of which have applications in nutraceuticals, pharmaceuticals, and longevity research. Traditional plant extraction and chemical synthesis struggle with cost and scalability, but metabolic engineering offers a cleaner, more efficient alternative. The review highlights shared biosynthetic pathways across structurally related compounds, making it easier to transfer engineering strategies between products. This work sets the stage for more sustainable, high-yield production of antioxidants tied to healthy aging.
Detailed Summary
Beta-carotene and its derivatives are among the most studied bioactive compounds in longevity and preventive medicine. As precursors to vitamin A, potent antioxidants, and modulators of oxidative stress, compounds like astaxanthin, zeaxanthin, and crocetin have drawn significant interest for their potential roles in slowing cellular aging, protecting vision, and reducing inflammation. However, sourcing these compounds reliably and affordably from plants or via chemical synthesis has long been a bottleneck.
This 2025 review from Imperial College London surveys recent progress in using yeast as microbial cell factories to produce beta-carotene and its structural relatives. The authors focus on two major yeast platforms — Saccharomyces cerevisiae and Yarrowia lipolytica — each offering distinct metabolic advantages. Key metabolic engineering strategies reviewed include pathway optimization, cofactor balancing, compartmentalization, and precursor supply enhancement.
A distinguishing feature of this review is its classification of beta-carotene derivatives into two functional groups: xanthophylls (canthaxanthin, zeaxanthin, astaxanthin, violaxanthin) and apocarotenoids (crocetin, retinol, beta-ionone, beta-cyclocitral, strigolactones). By identifying the shared biosynthetic logic within each group, the authors argue that engineering strategies are transferable across compounds, accelerating development timelines.
Fermentation optimization approaches — including carbon source selection, fed-batch strategies, and two-phase fermentation systems — are also discussed as critical levers for improving yields toward commercially viable levels.
The review acknowledges that while yeast-based production is promising, challenges remain around metabolic flux competition, toxicity of intermediates, and scaling fermentation economics. Future directions include expanding the range of yeast hosts and fine-tuning biosynthetic efficiency. For the longevity field, this work signals a near-term path to affordable, sustainable carotenoid nutraceuticals.
Key Findings
- Yeast platforms S. cerevisiae and Y. lipolytica can be engineered to produce diverse longevity-relevant carotenoids.
- Beta-carotene derivatives are classified into xanthophylls and apocarotenoids, sharing transferable biosynthetic engineering strategies.
- Metabolic engineering advances include pathway flux optimization, cofactor balancing, and subcellular compartmentalization.
- Fermentation optimization (fed-batch, two-phase systems) is critical for achieving commercially viable carotenoid yields.
- Yeast biosynthesis offers sustainability and scalability advantages over plant extraction or chemical synthesis.
Methodology
This is a comprehensive narrative review, not an original experimental study. The authors synthesized published literature on metabolic engineering and fermentation strategies in yeast for carotenoid biosynthesis, organizing findings by compound class and production host.
Study Limitations
As a review based only on the abstract, specific yield benchmarks and head-to-head comparisons between yeast strains cannot be assessed. Yeast-based production still faces hurdles including intermediate toxicity, metabolic competition, and fermentation scale-up costs. Clinical evidence linking microbially produced carotenoids to longevity outcomes was not addressed in this biotechnology-focused paper.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.